Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MDR

- PMLiVE

Pfizer and Merck expand anti-PD1 cancer alliance

Will investigate combination of pembrolizumab and Xalkori

- PMLiVE

EMA accepts Cubist antibiotic for review

Follows FDA priority review for ceftolozane/ tazobactam

- PMLiVE

ViiV bags US approval for HIV blockbuster-in-waiting

Drug combines antiretrovirals with Tivicay

- PMLiVE

US panel backs pneumococcal vaccines for seniors

Vaccines to be provided by Merck & Co and Pfizer

- PMLiVE

Pfizer to work with genetics firm on bowel disease

Agrees deal with 23andMe to research ulcerative colitis and Crohn’s disease

- PMLiVE

Pfizer closes on $1bn label expansion for Prevenar

EMA begins review of the pneumococcal vaccine

- PMLiVE

FDA approves antibacterial skin drug Orbactiv

US regulator authorises Medicines Company's treatment for ABSSSI

- PMLiVE

Pfizer’s arthritis drug Enbrel widens its European licence

Gains new indication for early-stage inflammatory joint disease

- PMLiVE

Pfizer acquires Baxter Men C and encephalitis vaccines for $635m

Snaps up marketed vaccines and part of Baxter's Austrian manufacturing plant

- PMLiVE

European licence for BMS/Pfizer’s Eliquis in DVT and PE

Anticoagulant catches up with Bayer's Xarelto and Boehringer's Pradaxa

- PMLiVE

Pfizer inks $360m deal to buy InnoPharma

Boosts position in the buoyant sterile injectables market

UK flag

Antimicrobial resistance priority for new UK science minister

Greg Clark announces collaboration led by Medical Research Council

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links